Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a fatal parasitic disease caused by trypanosomes. Current treatment options for HAT are scarce, toxic, no longer effective, or very difficult to administer, in particular for the advanced, fatal stage of the disease (stage 2, c...
Saved in:
Main Authors: | Els Torreele (Author), Bernadette Bourdin Trunz (Author), David Tweats (Author), Marcel Kaiser (Author), Reto Brun (Author), Guy Mazué (Author), Michael A Bray (Author), Bernard Pécoul (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2010-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fexinidazole: a potential new drug candidate for Chagas disease.
by: Maria Terezinha Bahia, et al.
Published: (2012) -
Agrochemicals against malaria, sleeping sickness, leishmaniasis and Chagas disease.
by: Matthias Witschel, et al.
Published: (2012) -
The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis.
by: Eric Pelfrene, et al.
Published: (2019) -
The Structure and Activity of Double-Nitroimidazoles. A Mini-Review
by: Justyna Żwawiak, et al.
Published: (2018) -
Tackling vaccine inequity in 2023: have we made progress?
by: Els Torreele
Published: (2024)